CytoSorbents – $11.5 Million Shelf Takedown

New York – April 19, 2017 – Cooley advised the underwriters on CytoSorbents’ $11.5 million shelf takedown of 2,555,555 shares of common stock.

Cowen and Company acted as the sole book-running manager for the offering. Aegis Capital Corp, Wainwright & Co., B. Riley & Co., Maxim Group LLC and Northland Capital Markets acted as co-managers.

CytoSorbents, which trades on The NASDAQ Capital Market under the symbol “CTSO,” is a leader in critical care immunotherapy. The company’s blood purification technology is approved in the European Union, with distribution in 29 countries around the world. CytoSorb is an extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.